Hydralazine injection Shortage
Last Updated: May 18, 2023
Status: Current
Products Affected - Description
-
- Hydralazine injection, Akorn, 20 mg/mL, 1 mL vial, 10 count, NDC 17478-0934-10 - discontinued
- Hydralazine injection, Mylan Institutional (Viatris), 20 mg/mL, 1 mL vial, 25 count, NDC 67457-0291-01 - discontinued
Reason for the Shortage
-
- Akorn ceased operations in February 2023.
- American Regent has hydralazine injection available.
- Eugia has hydralazine injection available.
- Fresenius Kabi has hydralazine injection available.
- Hikma has hydralazine injection available.
- Viatris discontinued hydralazine injection in April 2023.
- X-Gen is not currently manufacturing hydralazine injection.
Available Products
-
- Hydralazine injection, American Regent, 20 mg/mL, 1 mL vial, 25 count, NDC 00517-0901-25
- Hydralazine injection, Eugia US, 20 mg/mL, 1 mL vial, 25 count, NDC 55150-0400-25
- Hydralazine injection, Fresenius Kabi, 20 mg/mL, 1 mL vial, 25 count, NDC 63323-0614-01
- Hydralazine injection, Hikma, 20 mg/mL, 1 mL vial, 25 count, NDC 00641-6231-25
Estimated Resupply Dates
-
- All marketed presentations are available.
Updated
Updated May 18, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 4, 2018 by Anthony Trovato, PharmD, BCPS. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.